TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/healthscience?src=hash" target="_blank"gt;#healthsciencelt;/agt;–The Ontario Bioscience Innovation Organization (OBIO®) is proud to
announce its 2019
Capital Access Advisory Program (CAAP®) and the high-potential
health science companies in this year’s program.
Now in its seventh year, this year’s OBIO CAAP companies will work with
OBIO and a vast network of expert advisors over the next year to achieve
key goals and objectives which will position them for successful
financing. OBIO CAAP companies are advancing and accelerating the
development and commercialization of therapeutics, diagnostics, medical
devices and digital health products and services to benefit Ontario and
global human health.
“OBIO CAAP is a unique program for high-potential health science
companies in Ontario. They receive personalized coaching, access to a
global network of expert advisors, and strategic investor introductions
that will ultimately drive fundraising success and lead to business and
job growth,” said Gail Garland, OBIO President and CEO.
“This was an exciting year for RNA Diagnostics to be in the OBIO CAAP
program. Not only did we close a ‘Series A’ round of financing, we also
commenced a multi-site pivotal clinical trial of our RDA technology,”
said Jeremy Bridge-Cook, CEO of RNA Diagnostics. “Participating in the
OBIO CAAP in 2018/19 gave RNA Diagnostics access to leading investors at
OBIO investor summits held in Niagara-on-the-Lake and New York City. The
experienced OBIO team provided timely assistance and connected me with
expert advisors who provided valuable feedback on our investor
collaterals and strategy. I strongly recommend the OBIO CAAP program to
all scaling health science companies.”
Some of the cutting edge and high impact technologies that companies in
this year’s OBIO CAAP program are developing and commercializing
include: highly innovative therapeutics for cancer, next-generation
surgical tape to repair fractures, virtual reality based surgical
training tools, a gene delivery platform for chronic diseases, a
non-invasive diagnostic for Alzheimer’s disease, a camera that can
travel through veins and arteries, and a wearable blood purification
system for patients with kidney disease.
Learn more about the 2019 OBIO CAAP companies, their technologies
and products below:
| Company | Technology / Product | |||
|
Cohesys revolutionizes bone fracture treatments with BoneTape, a novel resorbable adhesive tape for craniomaxillofacial fracture fixation. |
||||
|
Empirica Therapeutics is developing a pipeline of innovative and transformative immunotherapies for cancers with substantial unmet need. |
||||
|
Marion Surgical has developed a virtual reality (VR) surgical rehearsal platform with haptics that allows practicing tomorrows surgery today. |
||||
|
Mediphage Bioceuticals is developing safe, effective, and accessible gene delivery platforms to unlock the therapeutic power of personalized, redoseable genetic medicine. |
||||
|
RetiSpec has developed a non-invasive, simple to use and inexpensive tool for detection of early Alzheimer’s disease biomarkers in the eye based on machine learning, paving the way for a widely adopted Alzheimer’s screening. |
||||
|
Talon Pharmaceutical is a medicinal chemistry company developing novel drugs for difficult to treat cancers including highly aggressive forms of brain and breast cancer with poor prognosis and limited treatment options. |
||||
|
Qidni Labs, Inc. is developing the world’s smallest blood purification system for millions of patients with kidney failure. The technology will be used as a wearable device that replaces dialysis, provides more frequent therapy and significantly improves the quality of life for kidney failure patients. |
||||
|
Tracery Ophthalmics Inc. is a clinical stage ocular imaging & health tech company that harnesses image-based and non-image-based health data, artificial intelligence and cloud computing for the development of new diagnostic tools and individualized therapeutic strategies for blinding eye disease, first focusing on Age-Related Macular Degeneration (AMD). |
||||
|
Vena Medical has developed the world’s smallest camera, capable of travelling through veins and arteries, changing the way physicians treat patients today, and creating a platform for brand new procedures tomorrow. |
||||
The OBIO Capital Access Advisory Program (CAAP®) is
an intensive goal driven program of coaching and targeted advisor and
investor introductions. The program drives fundraising success for
health science companies looking to raise post-seed funding and operates
downstream from existing entrepreneurship programs. It is a
collaborative initiative between OBIO, industry and investors. CAAP
harnesses the expertise and engagement from the Ontario health science
community and investors from across Canada and the U.S. to accelerate
growth of this important Ontario industry sector.
The Ontario Bioscience Innovation Organization (OBIO®) founded in
2009, is a not-for-profit, membership-based organization engaged in
strategy, programming, policy development and advocacy to further the
commercialization of Ontario’s human health technologies positioning
Ontario as a leader in the international marketplace. OBIO advances this
goal through collaborative partnerships with industry, the investment
community, academia, the health system and government.
For more information, please visit www.obio.ca
and follow OBIO on Twitter @OBIOscience
Contacts
Media Contact:
Gail Garland
President and CEO, OBIO
416-848-6839
ext. 101 I gailgarland@obio.ca